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Essentials
• Factor XIII (FXIII)-mediated fibrin crosslinking is delayed in hemophilia.
• We determined effects of FXIII cotreatment with hemostatic agents on clot parameters.
• FXIII cotreatment accelerated FXIII activation and crosslinking of fibrin and a 2 -antiplasmin.
• These data provide biochemical rationale for FXIII cotreatment in hemophilia. Despite treatment, some patients have prolonged bleeding. FXIII-A 2 B 2 (FXIII) is a protransglutaminase. During clot contraction, thrombin-activated FXIII (FXIIIa) crosslinks fibrin and a 2 -antiplasmin, which promotes red blood cell retention and increases clot stability and weight. We hypothesized that FXIII cotreatment in hemophilia would accelerate FXIII activation, leading to increased fibrin crosslinking. Methods: FVIII-deficient plasma and whole blood were clotted with or without hemostatic agents (FVIII, rFVIIa, FEIBA, or recombinant B-domain-deleted porcine FVIII [rpFVIII] ) and/or FXIII. The effects on FXIII activation, thrombin generation, fibrin and a 2 -antiplasmin crosslinking, clot formation and clot weight were measured by western blotting, calibrated automated thrombography, thromboelastography, and clot contraction assays. Results: As compared with FVIII-treated hemophilic plasma, FVIII + FXIII cotreatment accelerated FXIIIa formation without increasing thrombin generation. As compared with buffer-treated or FXIII-treated hemophilic plasma, FVIII treatment and FVIII + FXIII cotreatment increased the generation and amount of crosslinked fibrin, including achain-rich high molecular weight species and crosslinked a 2 -antiplasmin. In the presence of FVIII inhibitors, as compared with hemostatic treatments (rFVIIa, FEIBA, or rpFVIII) alone, FXIII cotreatment increased whole blood clot weight. Conclusion: In hemophilia A plasma and whole blood, FXIII cotreatment with hemostatic agents accelerated FXIIIa formation, increased the generation and amount of fibrin a-chain crosslinked species,
Introduction
Congenital hemophilia A and hemophilia B result from the absence or deficiency of factor VIII and FIX, respectively, and lead to delayed and reduced thrombin generation [1] [2] [3] [4] . The initial hemophilic clot forms slowly, and has an abnormal fibrin structure with thick fibrin fibers [5] [6] [7] . As compared with normal clots, this abnormal fibrin structure leads to increased clot permeability and susceptibility to lysis [6, 7] . Bleeding events are usually treated with replacement factors (recombinant or plasmaderived human FVIII or FIX) that restore thrombin generation and normalize clot structure and stability.
However, approximately 25% of hemophilia A patients and 1-10% of hemophilia B patients develop inhibitors of replacement factors [8, 9] . More rarely, non-hemophilic individuals develop hemophilia A because of acquired FVIII inhibitors [10] . Bleeding in hemophilic patients with inhibitors is treated with hemostatic agents, such as recombinant activated FVII (rFVIIa), plasma-derived anti-inhibitor coagulant complex (FEIBA), or recombinant porcine FVIII. These agents bypass or mimic the FVIII-FIX complex to increase thrombin generation and, ultimately, improve fibrin quality [2, 4, 6, 7, [11] [12] [13] [14] . Unfortunately, despite hemostatic therapy,~10-30% of hemophilic patients experience refractory bleeding [15] . In this setting, several treatment strategies may be used, including increased frequency or dose of the initial hemostatic therapy, sequential or concomitant use of hemostatic agents, or addition of antifibrinolytic agents [16] [17] [18] . However, use of these treatment strategies is limited by several factors, including insufficient laboratory monitoring capacity and concerns about thrombosis [19] , leaving patients at increased risk of morbidity and mortality [20] . Consequently, better understanding of hemophilic clot formation and stability is needed to develop safer therapeutic options.
Hemostatic clot formation requires the thrombinmediated cleavage of fibrinogen to fibrin, and activation of the plasma protransglutaminase FXIII-A 2 B 2 (FXIII). FXIII activation involves the thrombin-catalyzed cleavage of activation peptide(s) from FXIII-A subunits to yield FXIII-A 0 , followed by the calcium-promoted dissociation of FXIII-B to yield activated FXIII (FXIIIa) [21] . FXIIIa introduces e-N-(c-glutamyl)-lysyl crosslinks between fibrin c-chains and a-chains, and between fibrin and antifibrinolytic proteins (e.g. a 2 -antiplasmin), enhancing clot mechanical and biochemical stability [22] [23] [24] . Additionally, FXIIIa-mediated fibrin a-chain crosslinking promotes red blood cell (RBC) retention in clots, and consequently increases clot weight and determines clot composition [25, 26] .
FXIII activation occurs early during coagulation, but is delayed in hemophilic whole blood [3] . Like FVIII-deficient or FIX-deficient patients, FXIII-deficient patients show intracranial and intramuscular bleeding [27] , suggesting that hemophilic bleeding results, at least in part, from delayed or reduced FXIIIa-mediated crosslinking and fibrin stabilization. Several in vitro hemophilia studies have demonstrated that FXIII combined with either rFVIIa [28, 29] or FVIII [30] accelerates FXIII activation, increases clot density, decreases clot permeability, and improves clot stability [28] [29] [30] . Clinically, Ng et al. [31] administered rFVIIa and FXIII sequentially to a severe hemophilia A patient with refractory bleeding; this approach attenuated bleeding and improved the patient's clinical status. Collectively, these studies suggest that FXIII cotreatment enhances FXIIIa-mediated fibrin crosslinking; however, this mechanism has not been firmly established.
Herein, we demonstrate that, as compared with untreated and FVIII-treated hemophilia A plasma, FXIII cotreatment accelerates FXIII activation, and increases the rate and amount of fibrin a-chain and a 2 -antiplasmin crosslinking. Additionally, we used hemophilic whole blood with inhibitors to demonstrate that, as compared with rFVIIa-treated, FEIBA-treated or recombinant B-domain-deleted porcine FVIII (rpFVIII)-treated whole blood, FXIII cotreatment increases whole blood clot weight. Collectively, these findings provide a further mechanistic rationale for FXIII cotreatment in hemophilia. 5i ). For FXIII, the FXIII-A 0 band was normalized to an FXIII-A 0 loading control. For fibrin crosslinking, bands were normalized to corresponding Bb + b-chain. For a 2 -antiplasmin, crosslinked a 2 -antiplasmin bands were normalized to total a 2 -antiplasmin band at t = 0. Maximum rates of FXIII-A 0 , c-c dimer, high molecular weight (HMW) species and a 2 -antiplasmin formation were calculated by determining the slope of the points showing the maximum increase for each experiment. For this calculation, at least three points were used for all fits except for measurements of a 2 -antiplasmin crosslinking in the presence of FVIII + FXIII (two points). 
Materials and methods

Proteins
Results
As compared with FVIII treatment alone, FXIII cotreatment accelerates FXIII activation without increasing thrombin generation
Hemophilia is associated with delayed thrombin-dependent FXIII activation during plasma clot formation [3] . This observation suggests that mechanisms that enhance FXIII activation and/or activity may improve hemophilic clot quality. We tested this hypothesis by adding FVIII and FXIII, alone and in combination, to hemophilic plasma, and measuring the activation and level of FXIII-A 0 by western blotting. As compared with no treatment or FVIII treatment (alone), FXIII, alone or in combination with FVIII, increased the baseline (t = 0) FXIII-A level~1.8-fold (Fig. 1A) . As compared with untreated hemophilic plasma, FVIII treatment (alone) increased the maximum rate of FXIII activation (0.01 AE 0.01 AU min respectively, mean AE SEM; Fig. 1C ) and increased the FXIII-A 0 level (Fig. 1A,B) . As compared with FVIII treatment (alone), FVIII + FXIII cotreatment significantly increased the maximum rate of FXIII activation (0.20 AE 0.05 AU min -1 versus 0.33 AE 0.05 AU min -1 , respectively, P < 0.01; Fig. 1C ), but did not increase the FXIII-A 0 level (Fig. 1A,B) . To determine whether accelerated FXIII activation was attributable to increased thrombin generation, we measured thrombin generation in hemophilic plasma treated with FVIII and FXIII, alone and in combination. As compared with untreated hemophilic plasma, FVIII treatment (alone) decreased the time to peak, and increased the rate (velocity index), thrombin peak, and endogenous thrombin potential (Table 2) . However, addition of FXIII (alone or with FVIII) did not alter thrombin generation (Table 2) . Collectively, these data indicate that cotreatment of hemophilic plasma with FXIII and FVIII accelerated FXIII activation without increasing thrombin generation.
As compared with FVIII treatment alone, FXIII cotreatment increases fibrin crosslinking Despite improving fibrin formation, increasing clot density, and decreasing clot permeability, rFVIIa treatment does not fully restore fibrin crosslinking rates in hemophilic plasma [2, 6, 7] . These results suggest that, despite a normalized fibrin structure, the FXIII-dependent effects on fibrin remain insufficient, and may be improved with FXIII cotreatment. To test this premise, we added FVIII and FXIII, alone and in combination, to hemophilic plasma, and measured fibrin crosslinking by western blotting. As compared with untreated hemophilic plasma, FXIII (alone) did not increase the formation rate or levels of crosslinked fibrin species (Fig. 2) . However, as compared with untreated hemophilic plasma, FVIII treatment (alone) increased the maximum rate of c-c dimer formation (0.004 AE 0.001 AU min respectively, P < 0.02; Fig. 2E ) and significantly increased overall HMW species levels (0.67 AE 0.20 AU versus 1.60 AE 0.30 AU at 120 min, respectively, P < 0.01; Fig. 2A,D) . Combined, these data indicate that cotreatment of hemophilic plasma with FXIII and FVIII increases the rate of fibrin formation and the amount of fibrin crosslinking.
As compared with FVIII treatment alone, FXIII cotreatment accelerates a 2 -antiplasmin crosslinking
Previous studies showed that coadministration of supraphysiologic concentrations of FXIII with rFVIIa or plasma-derived FVIII enhances hemophilic clot stability (area under the TEG curve) [32, 33] . In addition to crosslinking fibrin, FXIIIa also crosslinks a 2 -antiplasmin to fibrin; this reaction is thought to retain a 2 -antiplasmin in clots during clot contraction and inhibit fibrinolysis.
To test this premise, we added FVIII and FXIII, alone and in combination, to hemophilic plasma, and measured a 2 -antiplasmin crosslinking by western blotting. As compared with untreated hemophilic plasma, FXIII (alone) and FVIII (alone) increased the rate of a 2 -antiplasmin crosslinking (0.001 AE 0.0003 AU min © 2017 International Society on Thrombosis and Haemostasis increased the amount of fully crosslinked a 2 -antiplasmin (0.05 AE 0.01 AU versus 0.26 AE 0.07 AU at 30 min, P < 0.0001; Fig. 3B ) and accelerated the rate of a 2 -antiplasmin crosslinking (0.013 AE 0.002 AU min -1 , P < 0.04; Fig. 3C ). Combined, these data indicate that FXIII cotreatment accelerates and increases the incorporation of antifibrinolytic a 2 -antiplasmin into the fibrin clot, and provides a rationale for the enhanced clot stability reported in previous studies [32, 33] .
As compared with standard hemostatic treatments alone, FXIII cotreatment increases clot weight in hemophilic whole blood with inhibitors
Finally, we investigated the effects of FXIII cotreatment on clotting parameters in whole blood from hemophilic patients with inhibitors. As compared with normal individuals, hemophilic patients have decreased plasma and whole blood clot weight [2, 3] , which has been attributed to decreased clot formation and fibrin mass [3] . Collectively, these results suggest that improving FXIIIamediated fibrin crosslinking may increase hemophilic clot formation and quality. To test this premise, we first added hemostatic agents (rFVIIa, FEIBA, or rpFVIII) alone or in combination with FXIII to hemophilic whole blood with inhibitors, and then measured clot formation by TEG. As compared with untreated hemophilic whole blood, treatment with hemostatic agents (rFVIIa, FEIBA, or rpFVIII), but not FXIII (alone), decreased R and K, and increased angle values (Table 3) . However, as compared with the respective hemostatic agent(s) alone, FXIII cotreatment did not significantly change any clot formation parameters assessed by TEG (Table 3) .
Recently, our laboratory determined that FXIIIamediated a-chain crosslinking promotes RBC retention and increases the weight of contracted whole blood clots [25, 26] . Given the effect of FXIII cotreatment on fibrin a-chain crosslinking, we tested the effect of FXIII cotreatment on contracted clot weight. In these assays, as compared with untreated hemophilic whole blood, FXIII (alone) did not increase whole blood clot weight (mean clot weight of 42.7 AE 5.0 mg versus 50.5 AE 6.6 mg, respectively, n = 12). As compared with untreated hemophilic whole blood, rFVIIa (alone) increased clot weight (46.0 AE 6.3 mg versus 61.9 AE 5.3 mg, respectively, n = 8; Fig. 4A ), but FEIBA or rpFVIII (alone) did not (FEIBA, 40.9 AE 7.2 mg versus 54.1 AE 2.4 mg, n = 5 [Fig. 4B] ; rpFVIII, 35.3 AE 5.7 mg versus 42.4 AE 6.0 mg, n = 8 [ Fig. 4C]) . Interestingly, as compared with treatment with the respective hemostatic agent(s) alone, FXIII cotreatment with rFVIIa, FEIBA or rpFVIII significantly increased clot weight (to 73.1 AE 6.7 mg, 64.9 AE 2.5 mg and 57.6 AE 7.1 mg, respectively; Fig. 4A-C) . Combined, these data suggest that FXIII cotreatment with rFVIIa, FEIBA or rpFVIII does not alter clot formation parameters assessed by TEG, but does increase contracted whole blood clot weight and can do so in the presence of platelets and inhibitors.
Discussion
Due to insufficient thrombin generation, hemophilic patients form an unstable initial clot with an abnormal fibrin structure [1] [2] [3] [4] [5] [6] [7] . Hemostatic agents increase thrombin generation, leading to increased fibrin formation, increased fibrin network density, and thinner fibrin fibers [4, 6, 7] . However, despite hemostatic therapies, some hemophilic patients experience prolonged bleeding. Given the well-established ability of FXIIIa to stabilize clots, FXIII treatment in hemophilia has been previously evaluated in vitro and in vivo [28] [29] [30] [31] . However, these studies did not directly assess the effects of FXIII cotreatment on fibrin or a 2 -antiplasmin crosslinking, or address the contribution of FXIIIa to contracted whole blood clot properties. Therefore, we sought to extend the published literature by determining the effects of FXIII cotreatment on FXIII activation, crosslinking, and clot weight. Herein, we demonstrated that FXIII cotreatment accelerated FXIII activation, which increased fibrin and a 2 -antiplasmin crosslinking. We additionally showed that, in hemophilic samples with inhibitors, FXIII cotreatment increased whole blood clot weight. Collectively, these data provide a further mechanistic rationale for FXIII cotreatment in hemophilia.
Our data show that the effects of FXIII on clot crosslinking and composition occur in the presence, but not in the absence, of conventional hemostatic agents. This finding probably reflects the indispensable role of thrombin in both the generation of fibrin and the activation of FXIII, and previous observations that both fibrin formation and FXIII activation are delayed in hemophilia [3] . Thus, in the absence of sufficient procoagulant activity, the addition of even supraphysiologic concentrations of FXIII, alone, to hemophilic plasma fails to improve clot formation. However, in the presence of conventional hemostatic agents that stimulate thrombin generation, both fibrin formation and FXIII activation are increased, and the addition of supraphysiologic concentrations of FXIII further accelerates FXIII activation, and consequently enhances fibrin and a 2 -antiplasmin crosslinking.
FXIIIa-mediated crosslinking of fibrin c-chains and a-chains and a 2 -antiplasmin is essential for clot biophysical and biochemical stability. FXIIIa-mediated c-chain crosslinks stabilize fibrin fiber branches, and a-chain crosslinks contribute to clot stiffness and resistance to lysis [23, 24] . Therefore, our data showing that cotreatment of hemophilic plasma with FXIII increases c-chain and a-chain crosslinks complement previous findings that FXIII cotreatment reduces clot permeability and increases whole blood clot stability [28] [29] [30] . FXIIIa-mediated a-chain crosslinking also promotes RBC retention in contracted clots [25, 26] , and we observed here that FXIII cotreatment increased the RBC content of hemophilic clots. Increased RBC retention in clots may further enhance clot stability, as RBCs decrease clot permeability, reduce plasmin generation, and increase resistance to lysis [34, 35] . Furthermore, during FXIIIa-mediated clot contraction, FXIII crosslinks a 2 -antiplasmin to fibrin a-chains [32, 33, 36] . The FXIIIamediated crosslinking of a 2 -antiplasmin within a contracted clot is essential for clot resistance to fibrinolysis [37, 38] . Therefore, our data showing that FXIII Table 3 Effect of hemostatic therapies with and without FXIII cotreatment on thromboelastography parameters Healthy controls
Clot time (R, min) cotreatment increases the rate and amount of a 2 -antiplasmin crosslinking supports previous TEG data showing that, in the presence of tissue-type plasminogen activator, FXIII cotreatment with rFVIIa or rFVIII increases whole blood clot stability [29, 30] . Collectively, these data suggest that cotreatment with FXIII augments hemostasis by increasing FXIIIa-mediated fibrin and a 2 -antiplasmin crosslinking. These data provide a mechanistic rationale for employing FXIII cotreatment strategies to manage refractory bleeding in hemophilic patients.
FXIII cotreatment offers several therapeutic advantages. First, FXIII has a relatively long half-life (9-19 days) that is suitable for prophylactic dosing [39] . Second, FXIII may work for both acute bleeds [40] and in postoperative patients, in whom FXIII levels are often reduced [41] . Third, FXIII treatment does not increase thrombin generation, and has not been associated with thromboembolic events [39] , reducing concerns about thrombotic risk if FXIII is used with hemostatic agents (FVIII, rFVIIa, FEIBA, or rpFVIII). Fourth, although FXIII requires intravenous administration, it does not require renal or hepatic metabolism, which is favorable in older patients with comorbidities. Consequently, FXIII cotreatment with hemostatic therapies (FVIII/FIX, rFVIIa, FEIBA, or rpFVIII) is an attractive treatment strategy during refractory bleeding.
Our study has potential limitations. First, FVIII inhibitors have variable inhibitory kinetics based on the targeted FVIII epitope, which may affect clot formation in different conditions [42] . However, our patient cohort was small and heterogeneous with regard to baseline FVIII activity and human and porcine FVIII inhibitor titers, and was therefore underpowered to establish whether interactions exist between inhibitor titers and response to FXIII cotreatment. Second, we were not able to measure thrombin generation in the hemophilic whole blood samples. However, FXIII did not alter thrombin generation in plasma, and the whole blood samples had normal platelet counts and showed no change in the clot time in TEG assays, suggesting that FXIII did not alter thrombin generation in whole blood assays. Third, our experiments focused on the effects of FXIII cotreatment in hemophilia A; however, hemophilia B patients can also develop inhibitors and experience refractory bleeding, despite hemostatic therapy. Accordingly, cotreatment with hemostatic agents and supraphysiologic concentrations of FXIII may also augment hemostasis in these patients. This premise will require direct testing in future studies. Fourth, our study, like previous studies, lacks supportive experiments obtained in preclinical animal models. One previous study used a saphenous vein bleeding model to test the effect of FXIII in FIX-deficient mice, but failed to detect an improved time to clot formation [30] . The lack of effect may reflect insensitivity of this model to FXIIIa-mediated effects on clot composition or resistance to fibrinolysis. Although venous thrombosis models have demonstrated sensitivity to FVIII and FXIII separately [25, 43, 44] , the relevance of intravascular thrombosis models to hemostasis following vascular injury is unclear. Further in vivo study awaits the development of hemostasis models that are sensitive to the effects of both hemostatic agents and FXIII activity.
In conclusion, our results demonstrate that FXIII cotreatment accelerates FXIII activation, resulting in increased a-chain-rich HMW crosslinked fibrin species and a 2 -antiplasmin crosslinking, and increases the weight of contracted hemophilic whole blood clots. Demonstration of these functional effects is an important next step in determining the operant mechanism. Moreover, demonstration of these effects in whole blood from inhibitor patients -the individuals who are most likely to receive this therapy during refractory bleeding episodesfills an important gap in the clinical development of this approach. Collectively, these findings provide further a mechanistic rationale for the use of FXIII with hemostatic agents in hemophilia. 
